Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for the twelve months ended 31 December 2017.
The event will be held at Davy’s at Woolgate Bar and Brasserie, Woolgate Exchange, 25 Basinghall Street, London, EC2V 5HA from 18:00 and will take the form of a Company presentation followed by a Q&A session. The presentation for the event will also be made available on the Company’s website.
Potential investors and shareholders who wish to attend the event should register their interest with Florence Chandler at IFC Advisory Ltd on florence.chandler@investor-focus.co.uk or on 020 3934 6636.
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhancedhaemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.
